Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
16 nov. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end...
Cocrystal Pharma Selected to Present at the World Antiviral Conference
10 nov. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
06 nov. 2020 08h00 HE
|
Cocrystal Pharma, Inc.
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
Cocrystal Pharma Provides Update on Influenza A Program
19 oct. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...
Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
02 oct. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District...
Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
08 sept. 2020 08h00 HE
|
Cocrystal Pharma, Inc.
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares
31 août 2020 12h05 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
26 août 2020 22h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
26 août 2020 17h35 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
06 août 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...